The Progesterone in Recurrent Miscarriage (PROMISE) trial involved 836 women with idiopathic recurrent miscarriage randomized to receive either 400 mg of vaginal micronized progesterone twice daily or placebo from the time of positive pregnancy test to 12 weeks gestation.